|
Prostatic Neoplasms
|
0.350 |
Biomarker
|
group |
BEFREE |
DHA also inhibits AKT(T308) but not AKT(S473) phosphorylation, alters PI(3,4,5)P3 (PIP3) and phospho-AKT(S473) protein localization, decreases pPDPK1(S241)-AKT and AKT-BAD interaction and suppresses prostate tumor growth.
|
23633519 |
2013 |
|
Prostatic Neoplasms
|
0.350 |
AlteredExpression
|
group |
BEFREE |
These results suggest that increased expression of BAD provides a proliferative advantage to prostate tumors, while BAD dephosphorylation increases sensitivity of prostate cancer cells to apoptosis.
|
19593445 |
2009 |
|
Prostatic Neoplasms
|
0.350 |
Biomarker
|
group |
CTD_human |
These results suggest that increased expression of BAD provides a proliferative advantage to prostate tumors, while BAD dephosphorylation increases sensitivity of prostate cancer cells to apoptosis.
|
19593445 |
2009 |
|
Prostatic Neoplasms
|
0.350 |
Biomarker
|
group |
CTD_human |
Bad expression influences time to androgen escape in prostate cancer.
|
17542986 |
2007 |
|
Prostatic Neoplasms
|
0.350 |
AlteredExpression
|
group |
LHGDN |
Diverse antiapoptotic signaling pathways activated by vasoactive intestinal polypeptide, epidermal growth factor, and phosphatidylinositol 3-kinase in prostate cancer cells converge on BAD.
|
16728406 |
2006 |
|
Prostatic Neoplasms
|
0.350 |
PosttranslationalModification
|
group |
LHGDN |
Epidermal growth factor protects prostate cancer cells from apoptosis by inducing BAD phosphorylation via redundant signaling pathways.
|
16847055 |
2006 |
|
Prostatic Neoplasms
|
0.350 |
PosttranslationalModification
|
group |
LHGDN |
Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.
|
11839683 |
2002 |
|
Malignant neoplasm of prostate
|
0.320 |
PosttranslationalModification
|
disease |
BEFREE |
Using pharmacological inhibitors and dominant-negative proteins, we showed that VIP-induced cytoprotection and BAD phosphorylation are mediated via both Ras/MAPK and PKA pathways in CSCs of prostate cancer LNCaP and C4-2 cells, but only PKA signaling was involved in CSCs of DUVIPR (DU145 prostate cancer cells ectopically expressing VIP receptor) and breast cancer MCF7 cells.
|
28569785 |
2017 |
|
Malignant neoplasm of prostate
|
0.320 |
Biomarker
|
disease |
CTD_human |
Combination of proliferative and apoptotic properties prompts prostate cancer cells to be "addicted" to increased levels of phosphorylated BAD.
|
19593445 |
2009 |
|
Malignant neoplasm of prostate
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Combination of proliferative and apoptotic properties prompts prostate cancer cells to be "addicted" to increased levels of phosphorylated BAD.
|
19593445 |
2009 |
|
Malignant neoplasm of prostate
|
0.320 |
Biomarker
|
disease |
CTD_human |
Bad expression influences time to androgen escape in prostate cancer.
|
17542986 |
2007 |
|
Transient Ischemic Attack
|
0.300 |
Biomarker
|
disease |
CTD_human |
Overexpression of copper/zinc superoxide dismutase in transgenic mice protects against neuronal cell death after transient focal ischemia by blocking activation of the Bad cell death signaling pathway.
|
12629175 |
2003 |
|
leukemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
|
12970779 |
2003 |
|
Posterior Circulation Transient Ischemic Attack
|
0.300 |
Biomarker
|
disease |
CTD_human |
Overexpression of copper/zinc superoxide dismutase in transgenic mice protects against neuronal cell death after transient focal ischemia by blocking activation of the Bad cell death signaling pathway.
|
12629175 |
2003 |
|
Carotid Circulation Transient Ischemic Attack
|
0.300 |
Biomarker
|
disease |
CTD_human |
Overexpression of copper/zinc superoxide dismutase in transgenic mice protects against neuronal cell death after transient focal ischemia by blocking activation of the Bad cell death signaling pathway.
|
12629175 |
2003 |
|
Transient Ischemic Attack, Vertebrobasilar Circulation
|
0.300 |
Biomarker
|
disease |
CTD_human |
Overexpression of copper/zinc superoxide dismutase in transgenic mice protects against neuronal cell death after transient focal ischemia by blocking activation of the Bad cell death signaling pathway.
|
12629175 |
2003 |
|
Crescendo Transient Ischemic Attacks
|
0.300 |
Biomarker
|
disease |
CTD_human |
Overexpression of copper/zinc superoxide dismutase in transgenic mice protects against neuronal cell death after transient focal ischemia by blocking activation of the Bad cell death signaling pathway.
|
12629175 |
2003 |
|
Brain Stem Ischemia, Transient
|
0.300 |
Biomarker
|
disease |
CTD_human |
Overexpression of copper/zinc superoxide dismutase in transgenic mice protects against neuronal cell death after transient focal ischemia by blocking activation of the Bad cell death signaling pathway.
|
12629175 |
2003 |
|
Transient Cerebral Ischemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Overexpression of copper/zinc superoxide dismutase in transgenic mice protects against neuronal cell death after transient focal ischemia by blocking activation of the Bad cell death signaling pathway.
|
12629175 |
2003 |
|
Transient Ischemic Attack, Anterior Circulation
|
0.300 |
Biomarker
|
disease |
CTD_human |
Overexpression of copper/zinc superoxide dismutase in transgenic mice protects against neuronal cell death after transient focal ischemia by blocking activation of the Bad cell death signaling pathway.
|
12629175 |
2003 |
|
Glioma
|
0.240 |
Biomarker
|
disease |
BEFREE |
Thus, our data suggest that glioma cell survival occurs through a novel PI (3)-kinase/PDK1/PKC-ι/BAD mediated pathway.
|
21419810 |
2011 |
|
Glioma
|
0.240 |
Biomarker
|
disease |
BEFREE |
Surprisingly, although siRNA-mediated depletion of BAD in glioma cells abrogates cytotoxic- and chemotherapy-induced apoptosis, TWEAK still displays a strong protective effect, suggesting that BAD serine 136 phosphorylation plays a minor role in TWEAK-Akt2-induced glioma cell survival.
|
19861406 |
2009 |
|
Glioma
|
0.240 |
Biomarker
|
disease |
BEFREE |
Inhibition of either PPARgamma or MEK1/2 blocked the Troglitazone-mediated phosphorylation of BAD and further increased the synergistic induction of glioma cell death by TRAIL and Troglitazone.
|
19158480 |
2008 |
|
Glioma
|
0.240 |
Biomarker
|
disease |
RGD |
pERK, pAkt and pBad: a possible role in cell proliferation and sustained cellular survival during tumorigenesis and tumor progression in ENU induced transplacental glioma rat model.
|
16944316 |
2006 |
|
Glioma
|
0.240 |
AlteredExpression
|
disease |
BEFREE |
The apoptotic death in the glioma cell lines treated with PPARgamma agonists was correlated with the transient up-regulation of Bax and Bad protein levels.
|
12065618 |
2002 |